【Sumitomo Pharma】Core Company of Pharmaceutical Business | June 25, 2026

Performance Overview

Sumitomo Pharma's core business is pharmaceuticals, operated under the control of its parent company, Sumitomo Chemical. The voting rights ownership ratio increased to over 45.84% as of March 2026, maintaining collaboration through transactions with the parent company and seconded employees. While detailed sales and profit figures are unspecified, the company's relationship with its parent and stable business foundation are demonstrated.

Future Outlook and Transaction Relationships

Sumitomo Pharma promotes its pharmaceutical business under the control of its parent company, collaborating on land acquisitions at research institutes and factories, as well as raw material procurement. The seconded employees and transactions from the parent company preserve managerial independence while maintaining cooperative relationships. Minority shareholder protections are also in place, aiming for stable future operations.